Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:58:07.122Z.
Calculation as of: 2026-10-06T18:58:07.122Z.
Quote observation: 2026-10-06T18:55:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0b6e81bfb968b053e3c664bae947515aab5c23e1d2a9854177de48c3869b2902
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$4.78B
EV/Sales Ratio
8.44x
TTM Avg
10.12x
3Y Avg
8.33x
5Y Avg
12.98x
Market Cap
$4.75B
EV/Sales Ratio
2436.16x
TTM Avg
1670.59x
3Y Avg
767.91x
5Y Avg
667.74x
Market Cap
$4.68B
EV/Sales Ratio
2.94x
TTM Avg
2.27x
3Y Avg
2.39x
5Y Avg
2.98x
Market Cap
$5.01B
EV/Sales Ratio
5.37x
TTM Avg
5.71x
3Y Avg
6.87x
5Y Avg
6.87x
Market Cap
$4.65B
EV/Sales Ratio
1.01x
TTM Avg
0.96x
3Y Avg
1.19x
5Y Avg
1.40x
Market Cap
$4.65B
EV/Sales Ratio
10.69x
TTM Avg
13.65x
3Y Avg
13.65x
5Y Avg
13.65x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | $4.83B | N/A | N/A | N/A | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.78B | 8.44x | 10.12x | 8.33x | 12.98x |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.75B | 2436.16x | 1670.59x | 767.91x | 667.74x |
| Erasca, Inc. (ERAS)vs › | $4.95B | N/A | N/A | N/A | N/A |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.68B | N/A | N/A | N/A | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 2.94x | 2.27x | 2.39x | 2.98x |
| Waystar Holding Corp. (WAY)vs › | $5.01B | 5.37x | 5.71x | 6.87x | 6.87x |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 1.01x | 0.96x | 1.19x | 1.40x |
| BillionToOne, Inc. (BLLN)vs › | $4.65B | 10.69x | 13.65x | 13.65x | 13.65x |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.05B | 3.43x | 3.38x | 3.94x | 3.84x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
